ReviewAnnals of pediatric cardiology
New hope for young hearts: A systematic review of sodium glucose cotransporter 2 inhibitors in pediatric heart failure.
Review in Annals of pediatric cardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Challenges in managing pediatric heart failure, especially in resource-limited settings.Annals of pediatric cardiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current management of pediatric heart failure (HF) remains challenging. The emergence of sodium glucose cotransporter 2 inhibitors (SGLT2i) offers potential benefits beyond their traditional use in diabetes care. This review aims to provide a comprehensive perspective on the potential of SGLT2i to address pediatric HF. A literature search was conducted across PubMed/MedLine, Scopus, Cochrane Library, and gray literature repositories. This review included studies on SGLT2i use in pediatric HF, focusing on patients aged 18 or younger. The quality of the studies was independently assessed by four reviewers, with discrepancies resolved by consensus. A narrative synthesis was conducted to evaluate the clinical outcomes reported across the included studies. The protocol was registered in the Prospective Register of Systematic Reviews (CRD420251051396). Five studies were included in the analysis. Studies have reported an increase in ejection fractions and a decrease in natriuretic peptide levels following treatment with SGLT2i. Echocardiographic findings generally suggested a positive impact on the severity of ventricular dilation and atrioventricular valve regurgitation. There were no significant changes in the hemodynamic status, liver function, blood glucose, and electrolyte levels; however, we observed a notable decrease in glomerular filtration rate, an increase in serum creatinine, an elevated risk of acute kidney injury, protein-losing enteropathy, persistent abdominal pain, and urinary tract infection. SGLT2i offers therapeutic promise in pediatric HF with an acceptable safety failure. Preliminary data support further investigations to guide clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.